Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

T.S. Larsen; N. Pallisgaard; M.T. Andersen; M.B. Moller; H.C. Hasselbalch; Ole Weis Bjerrum

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

T.S. Larsen, N. Pallisgaard, M.T. Andersen, M.B. Moller, H.C. Hasselbalch, Ole Weis Bjerrum

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

40 Citationer (Scopus)

Abstract

Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response
Udgivelsesdato: 2008/10

Originalsprog	Engelsk
Tidsskrift	Annals of Hematology
Vol/bind	87
Udgave nummer	10
Sider (fra-til)	847-850
Antal sider	3
ISSN	0939-5555
Status	Udgivet - 2008

Citationsformater

@article{2f53fe809ba011debc73000ea68e967b,

title = "Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera",

abstract = "Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response Udgivelsesdato: 2008/10",

author = "T.S. Larsen and N. Pallisgaard and M.T. Andersen and M.B. Moller and H.C. Hasselbalch and Bjerrum, {Ole Weis}",

year = "2008",

language = "English",

volume = "87",

pages = "847--850",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

AU - Larsen, T.S.

AU - Pallisgaard, N.

AU - Andersen, M.T.

AU - Moller, M.B.

AU - Hasselbalch, H.C.

AU - Bjerrum, Ole Weis

PY - 2008

Y1 - 2008

N2 - Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response Udgivelsesdato: 2008/10

AB - Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response Udgivelsesdato: 2008/10

M3 - Journal article

SN - 0939-5555

VL - 87

SP - 847

EP - 850

JO - Annals of Hematology

JF - Annals of Hematology

IS - 10

ER -